Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · IRONWOOD PHARMACEUTICALS INC (IRWD)

Ironwood raises 2026 LINZESS sales and revenue guidance after strong second quarter

Positive Impact 4 of 5 guidance Written later

Ironwood Pharmaceuticals reported second quarter 2026 total revenue of $113.0 million, up from $85.2 million a year earlier, and GAAP net income of $51.3 million, or $0.31 per diluted share, compared with $0.14 a year earlier. The company raised its full-year 2026 guidance for U.S. LINZESS net sales, total revenue and adjusted EBITDA, and repaid a $200 million convertible note at maturity from cash on hand.

Key points

  • Q2 2026 U.S. LINZESS net sales were $282.3 million, up 14% from $248.0 million in Q2 2025
  • Updated 2026 guidance: U.S. LINZESS net sales $1.15 to $1.20 billion (prior $1.125 to $1.175 billion); total revenue $460 to $485 million; adjusted EBITDA greater than $310 million
  • Cash and cash equivalents were $79.1 million at June 30, 2026, down from $215.5 million at end of 2025; $385.0 million drawn on the revolving credit facility
  • Ronald Silver serves as Interim CFO after Gregory Martini's resignation in May 2026

The filing

CompanyIRONWOOD PHARMACEUTICALS INC (IRWD)
Form8-K, current report
Filed with the SECAug 6, 2026, 7:12 AM ET
Accession number0001104659-26-091625

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 06, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.